Browsing by Author "Kalantzis, Dimitrios"

Now showing items 1-3 of 3

    • Article  

      Cost-effectiveness of leucoreduction for prevention of febrile non-haemolytic transfusion reactions 

      Tsantes, Argirio E.; Kyriakou, Elias; Nikolopoulos, Georgios K.; Stylos, D.; Sidhom, M.; Bonovas, Stefanos; Douramani, Panagiota; Kalantzis, Dimitrios; Kokoris, Styliani; Valsami, S.; Stamoulis, K.; Politou, M.; Foudoulaki-Paparizos, Leontini (2014)
      Background. The cost-effectiveness of universal leucoreduction of blood components remains unclear. When using leucoreduced red blood cells, the decrease in the rate of febrile non-haemolytic transfusion reactions (FNHTR) ...
    • Article  

      Laboratory Assessment of the Anticoagulant Activity of Dabigatran 

      Kyriakou, Elias; Ikonomidis, Ignatios; Stylos, D.; Bonovas, Stefanos; Papadakis, I.; Nikolopoulos, Georgios K.; Kokoris, Styliani; Kalantzis, Dimitrios; Economopoulou, Christine; Kopterides, Petros; Lekakis, John; Tsantes, Argirio E. (2015)
      Background: Our aim was to identify laboratory assays in order to assess the anticoagulant effects of dabigatran etexilate (DE). Methods: Twenty patients with nonvalvular atrial fibrillation treated on DE (110 mg per os ...
    • Article  

      Rituximab in combination with CNOP chemotherapy in patients withn previously untreated indolent non-Hodgkin's lymphoma 

      Economopoulos, T.; Fountzilas, George; Pavlidis, Nicholas; Kalantzis, Dimitrios; Papageorgiou, E.; Christodoulou, C.; Hamilos, G.; Nikolaides, C.; Dimopoulos, M. A. (2003)
      Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy. The purpose ...